{"title":"通过使用两种药物降低Cdk5水平来治疗阿尔茨海默病，每种药物都有不同的作用方式。","authors":"Jeffrey Fessel","doi":"10.1177/25424823251335870","DOIUrl":null,"url":null,"abstract":"<p><p>There is need to understand the direct cause and, therefore, the appropriate treatment, of Alzheimer's disease (AD). A Google search was used to discern a) the primary cause of AD, and b) its treatment. Activation of Cdk5 is the primary cause for AD. Activation of Cdk5 may be decreased by using two drugs, roscovitine and tamoxifen, each having a different mechanism of action. Clinical trials should validate the efficacy and safety of using roscovitine and tamoxifen.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"9 ","pages":"25424823251335870"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033570/pdf/","citationCount":"0","resultStr":"{\"title\":\"Potential cure of Alzheimer's disease by reducing the level of Cdk5 using two drugs, each with a different modus operandi.\",\"authors\":\"Jeffrey Fessel\",\"doi\":\"10.1177/25424823251335870\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>There is need to understand the direct cause and, therefore, the appropriate treatment, of Alzheimer's disease (AD). A Google search was used to discern a) the primary cause of AD, and b) its treatment. Activation of Cdk5 is the primary cause for AD. Activation of Cdk5 may be decreased by using two drugs, roscovitine and tamoxifen, each having a different mechanism of action. Clinical trials should validate the efficacy and safety of using roscovitine and tamoxifen.</p>\",\"PeriodicalId\":73594,\"journal\":{\"name\":\"Journal of Alzheimer's disease reports\",\"volume\":\"9 \",\"pages\":\"25424823251335870\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033570/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's disease reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25424823251335870\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25424823251335870","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Potential cure of Alzheimer's disease by reducing the level of Cdk5 using two drugs, each with a different modus operandi.
There is need to understand the direct cause and, therefore, the appropriate treatment, of Alzheimer's disease (AD). A Google search was used to discern a) the primary cause of AD, and b) its treatment. Activation of Cdk5 is the primary cause for AD. Activation of Cdk5 may be decreased by using two drugs, roscovitine and tamoxifen, each having a different mechanism of action. Clinical trials should validate the efficacy and safety of using roscovitine and tamoxifen.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
